# Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

> **NCT05552183** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 29 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** oral dose of 200 mg pacritinib twice daily (BID)

## Key facts

- **NCT ID:** NCT05552183
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-12
- **Primary completion:** 2024-06-10
- **Final completion:** 2024-06-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552183, "Study to Evaluate the Safety, Tolerability, and PK of Pacritinib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05552183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*